Bruker Corporation $BRKR Shares Acquired by Rhenman & Partners Asset Management AB

Key Points

• Rhenman & Partners increased its stake in Bruker by 25.1% in Q3 to 154,315 shares (about $5.01M), and institutional investors now own 79.52% of the company with large recent buys from firms like Orbis and AQR.
• Bruker reported a quarterly EPS miss ($0.59 vs. $0.65) while revenue beat at $977.2M and set FY2026 guidance of 2.100–2.150 EPS; the stock opened down ~4.7% at $36.68 and trades well below the consensus target of $50.38.
• Insider activity included VP Mark Munch selling 2,000 shares, insiders own 27.30% of the stock, and the company declared a quarterly dividend of $0.05 per share (0.5% yield) with an ex-dividend date of March 23.

Rhenman & Partners Asset Management AB increased its stake in Bruker Corporation (NASDAQ:BRKR - Free Report) by 25.1% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 154,315 shares of the medical research company's stock after purchasing an additional 31,000 shares during the quarter. Rhenman & Partners Asset Management AB owned about 0.10% of Bruker worth $5,014,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Orbis Allan Gray Ltd bought a new stake in shares of Bruker during the 2nd quarter worth about $192,735,000. AQR Capital Management LLC lifted its stake in shares of Bruker by 125.3% in the 2nd quarter. AQR Capital Management LLC now owns 3,326,820 shares of the medical research company's stock worth $137,065,000 after acquiring an additional 1,850,215 shares during the period. Sculptor Capital LP boosted its holdings in shares of Bruker by 18.3% in the second quarter. Sculptor Capital LP now owns 3,074,801 shares of the medical research company's stock valued at $126,682,000 after acquiring an additional 476,363 shares in the last quarter. Brown Advisory Inc. increased its stake in shares of Bruker by 13.9% during the second quarter. Brown Advisory Inc. now owns 2,746,163 shares of the medical research company's stock valued at $113,142,000 after acquiring an additional 336,026 shares during the period. Finally, Vaughan Nelson Investment Management L.P. increased its stake in shares of Bruker by 61.6% during the third quarter. Vaughan Nelson Investment Management L.P. now owns 2,090,155 shares of the medical research company's stock valued at $67,909,000 after acquiring an additional 796,510 shares during the period. Institutional investors own 79.52% of the company's stock.

Insider Transactions at Bruker

In other Bruker news, VP Mark Munch sold 2,000 shares of the firm's stock in a transaction dated Thursday, January 15th. The stock was sold at an average price of $49.20, for a total transaction of $98,400.00. Following the completion of the sale, the vice president directly owned 128,443 shares in the company, valued at approximately $6,319,395.60. This trade represents a 1.53% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Corporate insiders own 27.30% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on BRKR shares. Weiss Ratings reaffirmed a "sell (d+)" rating on shares of Bruker in a research note on Monday, December 29th. JPMorgan Chase & Co. raised their target price on Bruker from $50.00 to $55.00 and gave the company an "overweight" rating in a research note on Monday, December 15th. Zacks Research upgraded shares of Bruker from a "strong sell" rating to a "hold" rating in a research report on Monday, December 8th. UBS Group reissued a "neutral" rating and issued a $49.00 price target on shares of Bruker in a report on Friday, February 13th. Finally, Rothschild & Co Redburn set a $60.00 price objective on shares of Bruker in a research note on Thursday, November 20th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, five have issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average target price of $50.38.

Bruker Stock Down 4.7%

Shares of NASDAQ:BRKR opened at $36.68 on Friday. The firm has a 50 day simple moving average of $44.68 and a 200 day simple moving average of $41.00. Bruker Corporation has a 52 week low of $28.53 and a 52 week high of $56.22. The company has a debt-to-equity ratio of 0.75, a quick ratio of 0.87 and a current ratio of 1.73. The company has a market cap of $5.58 billion, a PE ratio of -244.53, a price-to-earnings-growth ratio of 2.19 and a beta of 1.19.

Bruker (NASDAQ:BRKR - Get Free Report) last posted its quarterly earnings data on Thursday, February 12th. The medical research company reported $0.59 earnings per share for the quarter, missing the consensus estimate of $0.65 by ($0.06). The firm had revenue of $977.20 million for the quarter, compared to analysts' expectations of $964.61 million. Bruker had a positive return on equity of 13.56% and a negative net margin of 0.25%.The company's revenue for the quarter was down .2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.76 earnings per share. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. As a group, research analysts expect that Bruker Corporation will post 2.69 earnings per share for the current year.

Bruker Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, April 7th. Investors of record on Monday, March 23rd will be given a dividend of $0.05 per share. This represents a $0.20 annualized dividend and a yield of 0.5%. The ex-dividend date of this dividend is Monday, March 23rd. Bruker's payout ratio is presently -133.33%.

Bruker Company Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker's product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.